Primary AldosteronismEliXirNCT07800858
Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism
A study testing baxdrostat in people with Primary Aldosteronism, run by Queen Mary University of London at 2 sites in United Kingdom.
Trial summary
The goal of this clinical trial is to find out whether treatment with baxdrostat changes aldosterone-producing activity in the adrenal glands of people with primary aldosteronism. The study will use specialised imaging to measure changes in the adrenal glands before and after treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Primary Aldosteronism
- What is being tested?
- baxdrostat
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 15 Sep 2026to 31 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female
- Age > 18 years at time of signing informed consent.
- Diagnosed with Primary Aldosteronism (PA) according to Endocrine Society guidelines
- Presence of one or more adrenal nodules, (diameter 0.5-2.5 cm) on CT, PET-CT, or MRI, with characteristics (e.g. washout) of adenomas
- Suppressed cortisol after overnight dexamethasone
- Willing to take baxdrostat for 6 months and attend follow-up visits
Show all 28Show fewer
- Willing to undergo PET-CT imaging
- Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening.
- Serum potassium (K+) level ≥ 3.5 and < 5.0 mmol/L
- Negative pregnancy test for female participants of childbearing potential
- Able and willing to provide written consent Exclusion criteria
- <18 years of age
- Current or prior treatment (within 1 month before screening) with angiotensin-receptor blockers in combination with ACEIs.
- Serum sodium level < 135 mmol/L at screening, determined as per central laboratory.
- The following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
- New York Heart Association functional Heart Failure class IV at Screening.
- Known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease.
- Known severe hepatic impairment.
- Uncontrolled diabetes with HbA1c > 10.0% (86 mmol/mol) at screening.
- Participants suspected to have severe cardiac hypertrophy.
- Treatment with any MRAs or potassium-sparing diuretics within 1 month prior to screening.
- Treatment with potassium binders within 1 month prior to screening.
- Is expected to receive or is receiving any of the exclusionary drugs such as strong inducers of cytochrome P450 (CYP) 3A, chronic (taken more than 3 times a week for more than 3 months) use of NSAIDs, MRAs or chronic use of systemic steroids.
- Treatment with K+ supplements is not prohibited but the use should be continuously assessed throughout the trial.
- Inability or unwillingness to undergo PET-CT imaging
- Significant comorbidities that would interfere with participation
- Pregnancy or breastfeeding
- Unable to give informed consent
Who cannot join
None listed.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom2 sites
Cambridge NHS Foundation Trust
Cambridge
Mark Gurnell, mg299@medschl.cam.ac.uk
Barts NHS Trust
London
William M Drake, w.m.drake@qmul.ac.uk
About this study
Official title: Effects of aLdosterone Inhibition by baXdrostat on Molecular Imaging of cytoReduction in Primary Aldosteronism and Hypertension
The goal of this clinical trial is to find out whether treatment with baxdrostat changes aldosterone-producing activity in the adrenal glands of people with primary aldosteronism. The study will use specialised imaging to measure changes in the adrenal glands before and after treatment.
Participants will receive baxdrostat for 24 weeks and will be followed for changes in their adrenal imaging, blood pressure and hormone levels. The study will also investigate whether changes caused by treatment continue after baxdrostat is stopped.
This is a single-group study, meaning that all participants receive baxdrostat and there is no placebo or comparison group.
Read the detailed description
Primary aldosteronism (PA) is a common cause of hypertension in which the adrenal glands produce excess aldosterone. In some participants, the source of excess aldosterone can be associated with a small adrenal nodule. Aldosterone synthase, encoded by the CYP11B2 gene, is the enzyme responsible for the final steps of aldosterone production.
Molecular imaging using [18F]-CETO PET-CT can be used to visualise aldosterone-producing tissue in the adrenal glands. This study will investigate whether treatment with the aldosterone synthase inhibitor baxdrostat produces a measurable reduction in aldosterone-producing activity on molecular imaging.
This is an open-label, single-arm experimental medicine study. All participants will receive baxdrostat and there is no placebo or control group. Participants will receive baxdrostat 2 mg once daily for 24 weeks. Molecular imaging will be performed before treatment and following the treatment period, allowing the adrenal imaging signal to be compared within the same participant before and after treatment.
The study is designed to investigate whether pharmacological inhibition of aldosterone synthase is associated with a quantitative reduction in the molecular imaging signal from aldosterone-producing adrenal tissue. It will also investigate whether changes in imaging are associated with changes in biochemical measures of aldosterone production and clinical measures such as blood pressure, and how long suppression of aldosterone production persists after treatment has ended.
[18F]-CETO PET-CT is performed following dexamethasone pretreatment to suppress background uptake and improve visualisation of aldosterone-producing adrenal tissue. The radioligand is administered intravenously and PET imaging is performed together with a low-dose anatomical CT scan. Imaging will be undertaken at St Bartholomew's Hospital or Cambridge University Hospitals.
Participants will undergo regular follow-up during and after treatment. Assessments include blood pressure measurements, blood tests for electrolytes and adrenal hormones, 24-hour urine collections for measurement of aldosterone-related biomarkers, and quality-of-life assessment. Follow-up after treatment will allow the investigators to assess whether biochemical and clinical effects of baxdrostat persist after treatment has stopped.
The study also provides an opportunity to investigate the relationship between molecular imaging findings and subsequent clinical management. Where participants subsequently undergo adrenalectomy or ablation as part of their usual clinical care, adrenal tissue may be used for exploratory laboratory analyses of aldosterone synthase expression and markers of apoptosis. Adrenalectomy or ablation is not a research intervention and is not required by the study.
The study uses a within-participant comparison of adrenal molecular imaging before and after baxdrostat treatment. Participants are stratified according to the characteristics of the largest [18F]-CETO-positive adrenal nodule, but there is no randomisation or allocation to different treatment groups.
The study is intended to improve understanding of the effects of aldosterone synthase inhibition on aldosterone-producing adrenal tissue. The findings may help clarify the relationship between biochemical suppression of aldosterone production and changes in adrenal molecular imaging, and may inform the development of future approaches to the treatment and investigation of primary aldosteronism.
- Conditions
- Primary Aldosteronism
- Being tested
- baxdrostat
- Keywords
- Primary aldosteronism, Aldosterone synthase, CYP11B2, [18F]-CETO, Baxdrostat, Molecular imaging, PET CT
- Medical subject headings
- Hyperaldosteronism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
baxdrostatDrug
Baxdrostat 2 mg administered orally once daily for 24 weeks as an aldosterone synthase inhibitor. Treatment begins after the baseline [18F]-CETO PET-CT has confirmed eligibility for study treatment.
| Study group | Role | What they receive |
|---|---|---|
| Baxdrostat | Experimental | Participants will receive baxdrostat 2 mg once daily for 24 weeks. All participants will receive the same intervention; there is no placebo or control group. Participants will undergo study assessments before, during and after treatment, including molecular imaging and biochemical assessments. Receives: Drug: baxdrostat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in total lesion uptake of [18F]-CETO in adrenal lesions
Change, between pre- and post-baxdrostat PET-CT images, in total [18F]-CETO-positive lesion uptake, calculated by multiplying the volume (ml) of each lesion by its mean standardised uptake value (SUVmean) (unitless) and summing these values across all lesions. SUVmean is a dimensionless ratio of measured to injected radioactivity. This calculation generates a single reported value, expressed in SUV·ml, the conventional unit for this measurement. [Each lesion will be defined according to the 2025 European Association of Nuclear Medicine guideline.]
Measured: Baseline to approximately 8 months
Secondary outcomes (15)
Change in SUVmax between pre- and post-baxdrostat PET-CT images
Change, between pre- and post-baxdrostat PET-CT images, in maximum standardised uptake value (SUVmax) (unitless) of individual [18F]-CETO-positive lesions. SUVmax is a dimensionless ratio of measured to administered radioactivity. Where more than one lesion is present, SUVmax will be measured separately for each lesion and the values averaged to provide a single participant-level result.
Measured: Baseline to approximately 8 months
Voxel level change between pre- and post-baxdrostat PET-CT images
Voxel-level change in standardised uptake value (SUV) (unitless) between corresponding voxels across [18F]-CETO-positive lesions in pre- and post-baxdrostat PET-CT images. Pre- and post-treatment images will be registered to permit comparison of corresponding voxels, and the mean difference in SUV between paired voxels will be reported. SUV is a dimensionless ratio of measured to injected radioactivity.
Measured: Baseline to approximately 8 months
Change in the individual components of the primary endpoint: 1. Volume
Change, between pre- and post-baxdrostat PET-CT images, in total volume (ml) of all [18F]-CETO-positive lesions. Where more than one lesion is present, individual lesion volumes will be summed to generate a single reported value.
Measured: Baseline to approximately 8 months
Change in the individual components of the primary endpoint - 2. mean SUV
Change, between pre- and post-baxdrostat PET-CT images, in mean standardised uptake value (SUVmean) (unitless) across all [18F]-CETO-positive lesions. Where more than one lesion is present, a single overall SUVmean will be calculated across all lesions. SUVmean is a dimensionless ratio of measured to injected radioactivity.
Measured: Baseline to approximately 8 months
Change in whole-adrenal [18F]-CETO uptake
Change, between pre- and post-baxdrostat PET-CT images, in whole adrenal gland uptake of [18F]-CETO, calculated as the total volume (ml) of adrenal tissue with SUV ≥4 multiplied by the mean standardised uptake value (SUVmean) (unitless) within that volume. This calculation generates a single reported value, expressed in SUV·ml, the conventional unit for this measurement. SUVmean is a dimensionless ratio of measured to injected radioactivity.
Measured: Baseline to approximately 8 months
Change in serum aldosterone 12 months after completion of baxdrostat treatment
Change, between the end of baxdrostat treatment and 12 months after the end of treatment, in serum aldosterone (pmol/L).
Measured: End of baxdrostat treatment (24 weeks) to 12 months after treatment.
Change in plasma renin activity 12 months after completion of baxdrostat treatment
Change, between the end of baxdrostat treatment and 12 months after the end of treatment, in plasma renin activity (nmol/L/hr).
Measured: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in 24-hour urinary tetrahydroaldosterone 12 months after completion of baxdrostat treatment
Change, between the end of baxdrostat treatment and 12 months after the end of treatment, in 24h urine tetrahydroaldosterone (micromoles per 24h).
Measured: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in systolic blood pressure 12 months after completion of baxdrostat treatment
Change, between the end of baxdrostat treatment (24 weeks) and 12 months after the end of treatment, in systolic blood pressure (mmHg).
Measured: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in aldosterone-to-renin ratio 12 months after completion of baxdrostat treatment
Change, between the end of baxdrostat treatment (24 weeks) and 12 months after the end of treatment, in the ratio of serum aldosterone (pmol/L) to plasma renin activity (nmol/L/hr). The single measure resulting from division of aldosterone by plasma renin activity, termed the aldosterone-to-renin ratio (ARR), is expressed in (pmol/L)/(nmol/L/hr).
Measured: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in serum 11-deoxycorticosterone after 12 weeks of baxdrostat treatment
Change, between baseline and 12 weeks of baxdrostat treatment, in serum 11-deoxycorticosterone (11-DOC) (pmol/L).
Measured: Baseline to 12 weeks
Change in serum 11-deoxycorticosterone after 24 weeks of baxdrostat treatment
Change, between baseline and 24 weeks of baxdrostat treatment, in serum 11-deoxycorticosterone (11-DOC) (pmol/L).
Measured: Baseline to 24 weeks
Change in serum 11-deoxycorticosterone 2 months after completion of baxdrostat treatment
Change, between baseline and 2 months after completion of baxdrostat treatment, in serum 11-deoxycorticosterone (11-DOC) (pmol/L).
Measured: Baseline to 2 months after completion of baxdrostat treatment
Change in serum 11-deoxycorticosterone 6 months after completion of baxdrostat treatment
Change, between baseline and 6 months after completion of baxdrostat treatment, in serum 11-deoxycorticosterone (11-DOC) (pmol/L).
Measured: Baseline to 6 months after completion of baxdrostat treatment
Change in serum 11-deoxycorticosterone 12 months after completion of baxdrostat treatment
Change, between baseline and 12 months after completion of baxdrostat treatment, in serum 11-deoxycorticosterone (11-DOC) (pmol/L).
Measured: Baseline to 12 months after completion of baxdrostat treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2026
- Study start15 Sep 2026 (estimated)
- Primary completion31 May 2028 (estimated)
- Study completion31 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary AldosteronismStudies of the same condition, open and under way.
- More trials run by Queen Mary University of LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single-arm, open-label experimental medicine study. All participants will receive the same intervention, baxdrostat 2 mg once daily for 24 weeks. There is no randomisation, placebo or control group. Participants will be stratified according to the characteristics of the largest \[18F\]-CETO-positive adrenal nodule for study analysis.
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Collaborators
- AstraZeneca
- Responsible party
- Sponsor
- Investigators
- Morris J Brown, FMedSci, FRS, Principal investigator, Queen Mary University of London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07800858
- Sponsor's protocol ID
- 371884
- Acronym
- EliXir
- Status last verified
- Aug 2026
- First submitted
- 20 Aug 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of aLdosterone Inhibition by baXdrostat on Molecular Imaging of cytoReduction in Primary Aldosteronism and Hypertension
- ClinicalTrials.gov ID
- NCT07800858
- Acronym / sponsor ID
- EliXir / 371884
- Conditions
- Primary Aldosteronism
- Keywords
- Primary aldosteronism, Aldosterone synthase, CYP11B2, [18F]-CETO, Baxdrostat, Molecular imaging, PET CT
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Collaborators
- AstraZeneca
- Study start
- 15 Sep 2026 (estimated)
- Primary completion
- 31 May 2028 (estimated)
- Study completion
- 31 May 2028 (estimated)
- First posted
- 2 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to find out whether treatment with baxdrostat changes aldosterone-producing activity in the adrenal glands of people with primary aldosteronism. The study will use specialised imaging to measure changes in the adrenal glands before and after treatment.
Participants will receive baxdrostat for 24 weeks and will be followed for changes in their adrenal imaging, blood pressure and hormone levels. The study will also investigate whether changes caused by treatment continue after baxdrostat is stopped.
This is a single-group study, meaning that all participants receive baxdrostat and there is no placebo or comparison group.
Detailed description
Primary aldosteronism (PA) is a common cause of hypertension in which the adrenal glands produce excess aldosterone. In some participants, the source of excess aldosterone can be associated with a small adrenal nodule. Aldosterone synthase, encoded by the CYP11B2 gene, is the enzyme responsible for the final steps of aldosterone production.
Molecular imaging using [18F]-CETO PET-CT can be used to visualise aldosterone-producing tissue in the adrenal glands. This study will investigate whether treatment with the aldosterone synthase inhibitor baxdrostat produces a measurable reduction in aldosterone-producing activity on molecular imaging.
This is an open-label, single-arm experimental medicine study. All participants will receive baxdrostat and there is no placebo or control group. Participants will receive baxdrostat 2 mg once daily for 24 weeks. Molecular imaging will be performed before treatment and following the treatment period, allowing the adrenal imaging signal to be compared within the same participant before and after treatment.
The study is designed to investigate whether pharmacological inhibition of aldosterone synthase is associated with a quantitative reduction in the molecular imaging signal from aldosterone-producing adrenal tissue. It will also investigate whether changes in imaging are associated with changes in biochemical measures of aldosterone production and clinical measures such as blood pressure, and how long suppression of aldosterone production persists after treatment has ended.
[18F]-CETO PET-CT is performed following dexamethasone pretreatment to suppress background uptake and improve visualisation of aldosterone-producing adrenal tissue. The radioligand is administered intravenously and PET imaging is performed together with a low-dose anatomical CT scan. Imaging will be undertaken at St Bartholomew's Hospital or Cambridge University Hospitals.
Participants will undergo regular follow-up during and after treatment. Assessments include blood pressure measurements, blood tests for electrolytes and adrenal hormones, 24-hour urine collections for measurement of aldosterone-related biomarkers, and quality-of-life assessment. Follow-up after treatment will allow the investigators to assess whether biochemical and clinical effects of baxdrostat persist after treatment has stopped.
The study also provides an opportunity to investigate the relationship between molecular imaging findings and subsequent clinical management. Where participants subsequently undergo adrenalectomy or ablation as part of their usual clinical care, adrenal tissue may be used for exploratory laboratory analyses of aldosterone synthase expression and markers of apoptosis. Adrenalectomy or ablation is not a research intervention and is not required by the study.
The study uses a within-participant comparison of adrenal molecular imaging before and after baxdrostat treatment. Participants are stratified according to the characteristics of the largest [18F]-CETO-positive adrenal nodule, but there is no randomisation or allocation to different treatment groups.
The study is intended to improve understanding of the effects of aldosterone synthase inhibition on aldosterone-producing adrenal tissue. The findings may help clarify the relationship between biochemical suppression of aldosterone production and changes in adrenal molecular imaging, and may inform the development of future approaches to the treatment and investigation of primary aldosteronism.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a single-arm, open-label experimental medicine study. All participants will receive the same intervention, baxdrostat 2 mg once daily for 24 weeks. There is no randomisation, placebo or control group. Participants will be stratified according to the characteristics of the largest [18F]-CETO-positive adrenal nodule for study analysis.
| Arm | Type | Receives |
|---|---|---|
| Baxdrostat | Experimental | Drug: baxdrostatParticipants will receive baxdrostat 2 mg once daily for 24 weeks. All participants will receive the same intervention; there is no placebo or control group. Participants will undergo study assessments before, during and after treatment, including molecular imaging and biochemical assessments. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (28 listed)
- Male or female
- Age > 18 years at time of signing informed consent.
- Diagnosed with Primary Aldosteronism (PA) according to Endocrine Society guidelines
- Presence of one or more adrenal nodules, (diameter 0.5-2.5 cm) on CT, PET-CT, or MRI, with characteristics (e.g. washout) of adenomas
- Suppressed cortisol after overnight dexamethasone
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| baxdrostatBaxdrostat 2 mg administered orally once daily for 24 weeks as an aldosterone synthase inhibitor. Treatment begins after the baseline [18F]-CETO PET-CT has confirmed eligibility for study treatment. | Drug | Baxdrostat |
Primary outcome
Change in total lesion uptake of [18F]-CETO in adrenal lesions
Time frame: Baseline to approximately 8 months
Change, between pre- and post-baxdrostat PET-CT images, in total [18F]-CETO-positive lesion uptake, calculated by multiplying the volume (ml) of each lesion by its mean standardised uptake value (SUVmean) (unitless) and summing these values across all lesions. SUVmean is a dimensionless ratio of measured to injected radioactivity. This calculation generates a single reported value, expressed in SUV·ml, the conventional unit for this measurement. [Each lesion will be defined according to the 2025 European Association of Nuclear Medicine guideline.]
15 secondary outcomes
Change in SUVmax between pre- and post-baxdrostat PET-CT images
Time frame: Baseline to approximately 8 months
Voxel level change between pre- and post-baxdrostat PET-CT images
Time frame: Baseline to approximately 8 months
Change in the individual components of the primary endpoint: 1. Volume
Time frame: Baseline to approximately 8 months
Change in the individual components of the primary endpoint - 2. mean SUV
Time frame: Baseline to approximately 8 months
Change in whole-adrenal [18F]-CETO uptake
Time frame: Baseline to approximately 8 months
Change in serum aldosterone 12 months after completion of baxdrostat treatment
Time frame: End of baxdrostat treatment (24 weeks) to 12 months after treatment.
Change in plasma renin activity 12 months after completion of baxdrostat treatment
Time frame: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in 24-hour urinary tetrahydroaldosterone 12 months after completion of baxdrostat treatment
Time frame: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in systolic blood pressure 12 months after completion of baxdrostat treatment
Time frame: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in aldosterone-to-renin ratio 12 months after completion of baxdrostat treatment
Time frame: End of baxdrostat treatment (24 weeks) to 12 months after treatment
Change in serum 11-deoxycorticosterone after 12 weeks of baxdrostat treatment
Time frame: Baseline to 12 weeks
Change in serum 11-deoxycorticosterone after 24 weeks of baxdrostat treatment
Time frame: Baseline to 24 weeks
Change in serum 11-deoxycorticosterone 2 months after completion of baxdrostat treatment
Time frame: Baseline to 2 months after completion of baxdrostat treatment
Change in serum 11-deoxycorticosterone 6 months after completion of baxdrostat treatment
Time frame: Baseline to 6 months after completion of baxdrostat treatment
Change in serum 11-deoxycorticosterone 12 months after completion of baxdrostat treatment
Time frame: Baseline to 12 months after completion of baxdrostat treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Primary Aldosteronism
Not yet recruitingPhase 2
SYH2072 Tablets in Participants With Primary Aldosteronism
Primary Aldosteronism
Recruiting
Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
Hyperaldosteronism; Primary, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Active, not recruiting
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Primary Aldosteronism, Resistant Hypertension
RecruitingObservational study
Kidney Stiffness Measured by Ultrasound in Patients With High Blood Pressure and Healthy Volunteers
Arterial Hypertension, Chronic Kidney Disease, Primary Aldosteronism
Active, not recruiting
Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA
Primary Aldosteronism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Morris J Brown, FMedSci, FRS principal investigator
Queen Mary University of London
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing baxdrostat in people with Primary Aldosteronism, run by Queen Mary University of London at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 28 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aklima Khatun (0203 465 8577, aklima.khatun4@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in total lesion uptake of [18F]-CETO in adrenal lesions (time frame: Baseline to approximately 8 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.